Jared Green, DO
Cardiovascular Disease · West Reading, PANPI 1104912708
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,050 of the $44,071 with a category attached, or 77.3%. Scpharmaceuticals Inc. accounts for 68.4% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $31,590, more than ten times the $1,173 reported in 2019. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $138.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scpharmaceuticals Inc.$30K
- Impulse Dynamics (USA) Inc.$8K
- Pfizer$2K
- Abbott$1K
- E.r. Squibb & Sons, L.L.C.$873
- Novartis$482
- plus $2K from 20 others
Across 99 payments — averaging $1579.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$77K
- Impulse Dynamics (USA) Inc.$60K
- Fujirebio Diagnostics, Incorporated$19K
What the payments were for
- Consulting fees$1,2003%
- Speaking & faculty fees$34,05077%
- Travel & lodging$5191%
- Food & beverage$8,28219%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scpharmaceuticals Inc. | 31 | $30,129 |
| Impulse Dynamics (USA) Inc. | 45 | $8,001 |
| Pfizer | 75 | $1,501 |
| Abbott | 19 | $1,202 |
| E.r. Squibb & Sons, L.L.C. | 45 | $873 |
| Novartis | 33 | $482 |
| Johnson & Johnson | 21 | $441 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $257 |
| ZOLL Respicardia, Inc. | 2 | $224 |
| AstraZeneca | 10 | $192 |
| Boston Scientific | 2 | $162 |
| Boehringer Ingelheim | 4 | $156 |
| Akcea Therapeutics, Inc. | 3 | $102 |
| Atricure, Inc. | 1 | $59 |
| Medtronic | 1 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Mannkind Corporation | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| United Therapeutics Corporation | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Amgen | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FUROSCIX$29,542
- OPTIMIZER$10,141
- OPTIMIZER SMART SYSTEM$1,434
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$463
- remede System$224
- GENERAL PAIN MANAGEMENT$146
- VYNDAQEL$124
How this compares
$44,071 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 18 | $448,118 |
| EliquisApixaban | 210 | $237,692 |
| EntrestoSacubitril/Valsartan | 109 | $145,449 |
| JardianceEmpagliflozin | 94 | $107,045 |
| XareltoRivaroxaban | 39 | $53,080 |
| FarxigaDapagliflozin Propanediol | 44 | $48,405 |
| VerquvoVericiguat | 14 | $18,212 |
| Repatha SureclickEvolocumab | 15 | $11,322 |
| BrilintaTicagrelor | 11 | $5,867 |
| Metoprolol Succinate | 245 | $4,550 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,809 |
| Atorvastatin Calcium | 128 | $1,624 |
| Potassium Chloride | 50 | $1,409 |
| Carvedilol | 115 | $1,228 |
| Losartan Potassium | 80 | $1,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $1,501 | $685,810228 claims |
| NovartisEntresto | $482 | $145,449109 claims |
| Boehringer IngelheimJardiance | $156 | $107,04594 claims |
| AstraZenecaFarxiga, Brilinta | $192 | $54,27255 claims |
| Johnson & JohnsonXarelto | $441 | $53,08039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in West Reading
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
- Rajesh DaveCamp Hill$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.